Biogen Idec Inc (BIIB) 322.22 $BIIB
Biogen's Profit Rolls Amid Recent Drug Launches
at Investor's Business Daily - Fri Jul 11, 6:14PM CDT
Profit at big-cap biotech stock Biogen Idec (BIIB) has risen every year since 1998, even climbing through recessions, thanks to strong drug offerings. The trend is expected to continue, with profit this year expected to rise 29% to $11.53 a share,...
Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 4:30PM CDT
Bristol-Myers (BMY) will seek FDA approval for Opdivo in advanced melanoma by Sep 30.
Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...
Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.
Sarepta Therapeutics Slumps: SRPT Tanks 12.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 7:42AM CDT
Sarepta Therapeutics has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Should You Get Rid of Kamada (KMDA) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 7:34AM CDT
Kamada one such stock that can be considered to drop as it has witnessed a significant price decline and has seen negative earnings estimate
Regado's REGULATE-PCI Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:30PM CDT
The FDA has placed a clinical hold on patient enrollment and dosing in Regado Biosciences, Inc.'s (RGDO) ongoing phase III REGULATE-PCI study.
Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.
Lexicon (LXRX) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:46AM CDT
Lexicon (LXRX) was a big mover last session, with shares rising nearly 8% on the day.
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM
at The Street - Thu Jul 10, 5:00AM CDT
Cramer says Williams is a bargain, Unum is a slow and steady grower and Alcoa is reinventing itself.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:11AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:33AM CDT
Ultragenyx Pharmaceutical has seen flat earnings estimate revisions for the current quarter along with a significant rise in its share price for the past day
'Fast Money' Recap: Waiting for the Dust to Settle
at The Street - Wed Jul 09, 4:00AM CDT
The trading panel discussed the market's fall and how to hedge your positions.
Sanofi's Basal Insulin Candidate Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:40PM CDT
Sanofi's (SNY) new drug application for its basal insulin candidate, Toujeo, has been accepted for review by the FDA.
Biogen Idec Falls 2.48% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 2.48% Loss
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Jumps after Pain Drug Performs Well in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 3:45PM CDT
BioDelivery announced positive top-line results from a pivotal phase III efficacy study evaluating their pain candidate, BEMA buprenorphine.
Biogen's Profit Rolls Amid Recent Drug Launches
at Investor's Business Daily - Fri Jul 11, 6:14PM CDT
Profit at big-cap biotech stock Biogen Idec (BIIB) has risen every year since 1998, even climbing through recessions, thanks to strong drug offerings. The trend is expected to continue, with profit this year expected to rise 29% to $11.53 a share,...
Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 4:30PM CDT
Bristol-Myers (BMY) will seek FDA approval for Opdivo in advanced melanoma by Sep 30.
Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...
Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.
Sarepta Therapeutics Slumps: SRPT Tanks 12.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 7:42AM CDT
Sarepta Therapeutics has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Should You Get Rid of Kamada (KMDA) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 7:34AM CDT
Kamada one such stock that can be considered to drop as it has witnessed a significant price decline and has seen negative earnings estimate
Regado's REGULATE-PCI Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:30PM CDT
The FDA has placed a clinical hold on patient enrollment and dosing in Regado Biosciences, Inc.'s (RGDO) ongoing phase III REGULATE-PCI study.
Myriad Genetics Poised on Strong Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:10PM CDT
On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. (MYGN).
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.
Lexicon (LXRX) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:46AM CDT
Lexicon (LXRX) was a big mover last session, with shares rising nearly 8% on the day.
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM
at The Street - Thu Jul 10, 5:00AM CDT
Cramer says Williams is a bargain, Unum is a slow and steady grower and Alcoa is reinventing itself.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:11AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:33AM CDT
Ultragenyx Pharmaceutical has seen flat earnings estimate revisions for the current quarter along with a significant rise in its share price for the past day
'Fast Money' Recap: Waiting for the Dust to Settle
at The Street - Wed Jul 09, 4:00AM CDT
The trading panel discussed the market's fall and how to hedge your positions.
Sanofi's Basal Insulin Candidate Under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:40PM CDT
Sanofi's (SNY) new drug application for its basal insulin candidate, Toujeo, has been accepted for review by the FDA.
Biogen Idec Falls 2.48% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 2.48% Loss
Comtex SmarTrend(R) - Tue Jul 08, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $316.91 to a high of $324.60. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $324.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Jumps after Pain Drug Performs Well in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 3:45PM CDT
BioDelivery announced positive top-line results from a pivotal phase III efficacy study evaluating their pain candidate, BEMA buprenorphine.
